Well Shine Bio

Wellshine Biotechnology is a clinical-stage biopharmaceutical company based in Taiwan, dedicated to developing innovative treatments for metabolic disorders, oncology, and inflammatory diseases. The company's lead candidate, WS-012, is a long-acting tri-agonist targeting the GLP-1, GIP, and glucagon receptors for the treatment of Type 2 diabetes and non-alcoholic steatohepatitis (NASH). Wellshine leverages its proprietary drug discovery platform, Well-Discovery, to design multi-functional peptides and small molecules with improved efficacy and safety profiles. The company is publicly traded on the Taiwan Emerging Stock Market and continues to expand its pipeline into autoimmune and oncology indications. Its R&D strategy focuses on addressing significant unmet medical needs through the optimization of multi-targeting therapeutic agents.